531 related articles for article (PubMed ID: 25855404)
1. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.
Furnari FB; Cloughesy TF; Cavenee WK; Mischel PS
Nat Rev Cancer; 2015 May; 15(5):302-10. PubMed ID: 25855404
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
[TBL] [Abstract][Full Text] [Related]
3. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
4. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy.
Skoda J; Neradil J; Zitterbart K; Sterba J; Veselska R
Oncol Rep; 2014 Jan; 31(1):480-7. PubMed ID: 24270553
[TBL] [Abstract][Full Text] [Related]
5. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
[TBL] [Abstract][Full Text] [Related]
8. Updated Insights on EGFR Signaling Pathways in Glioma.
Oprita A; Baloi SC; Staicu GA; Alexandru O; Tache DE; Danoiu S; Micu ES; Sevastre AS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435537
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma.
Jun HJ; Bronson RT; Charest A
Stem Cells; 2014 Feb; 32(2):338-48. PubMed ID: 24115218
[TBL] [Abstract][Full Text] [Related]
10. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
11. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
Thomas C; Ely G; James CD; Jenkins R; Kastan M; Jedlicka A; Burger P; Wharen R
Acta Neuropathol; 2001 Jun; 101(6):605-15. PubMed ID: 11515790
[TBL] [Abstract][Full Text] [Related]
15. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
[TBL] [Abstract][Full Text] [Related]
16. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
Binder ZA; Thorne AH; Bakas S; Wileyto EP; Bilello M; Akbari H; Rathore S; Ha SM; Zhang L; Ferguson CJ; Dahiya S; Bi WL; Reardon DA; Idbaih A; Felsberg J; Hentschel B; Weller M; Bagley SJ; Morrissette JJD; Nasrallah MP; Ma J; Zanca C; Scott AM; Orellana L; Davatzikos C; Furnari FB; O'Rourke DM
Cancer Cell; 2018 Jul; 34(1):163-177.e7. PubMed ID: 29990498
[TBL] [Abstract][Full Text] [Related]
18. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
Klingler-Hoffmann M; Fodero-Tavoletti MT; Mishima K; Narita Y; Cavenee WK; Furnari FB; Huang HJ; Tiganis T
J Biol Chem; 2001 Dec; 276(49):46313-8. PubMed ID: 11514572
[TBL] [Abstract][Full Text] [Related]
19. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
20. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
